| Name | Title | Contact Details |
|---|---|---|
Samuel Maeder |
Information Security Director | Profile |
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.
We aim to make personalized brain health a reality.For everyone. Linus Health integrates the latest in cutting-edge neuroscience and AI technology with everyday digital tools to give individuals and their care professionals up-to-the-minute brain healt...
New York County Health Services is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Ohio State University Medical Center (OSUMC) is a multidisciplinary academic medical center located in Columbus, Ohio
Chem Rx Corporation, formerly Paramount Acquisition Corp., provides institutional pharmacy services to skilled nursing facilities, assisted living facilities, residential living facilities, addiction treatment centers and other long-term healthcare